(Reuters) - Shares of Gilead Sciences Inc closed down 6 percent on Tuesday, after a pharmacy benefit manager said it would cover both Gilead and rival AbbVie Inc's hepatitis C offering, renewing concerns of pricing pressure.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment